Previous studies have shown the therapeutic potential of sotrastaurin, a selective protein kinase C inhibitor, in patients with CD79A/B mutant DLBCL, whereas CARD11 mutations rendered insensitive [57]. This evidence concerns the gene CD79A and diffuse large B-cell lymphoma.